SC 13G/A: Scinai Immunotherapeutics Ltd.
Ticker: SCNI · Form: SC 13G/A · Filed: 2024-08-20T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Scinai Immunotherapeutics Ltd..
Risk Assessment
Risk Level: low
From the Filing
0000912282-24-000580.txt : 20240820 0000912282-24-000580.hdr.sgml : 20240820 20240820150601 ACCESSION NUMBER: 0000912282-24-000580 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240820 DATE AS OF CHANGE: 20240820 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-89384 FILM NUMBER: 241224664 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: STONE DANIEL E. CENTRAL INDEX KEY: 0001948744 ORGANIZATION NAME: FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 1200 BRICKELL AVENUE, #1470 CITY: MIAMI STATE: FL ZIP: 33131 SC 13G/A 1 13g.htm AMENDMENT 3 TO SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   Amendment No. 3 to SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 SCINAI IMMUNOTHERAPEUTCS LTD. (Name of Issuer) American Depositary Shares, each representing 4,000 Ordinary Shares, no par value (Title of Class of Securities) 09073Q203 (CUSIP Number) August 19, 2024 (Date of Event Which Requires Filing of This Statement) Check the Appropriate box to designate the rule pursuant to which this schedule is filed:          Rule 13d-1(b) X  Rule 13d-1(c)       Rule 13d-1(d) 1 NAME OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS     DANIEL E. STONE 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) (b)         3 SEC USE ONLY         4 CITIZENSHIP OR PLACE OF ORGANIZATION   United States   5 SOLE VOTING POWER NUMBER OF   62,400 SHARES 6 SHARED VOTING POWER BENEFICIALLY   0 OWNED BY 7 SOLE DISPOSITIVE POWER EACH   62,400 REPORTING 8 SHARED DISPOSITIVE POWER PERSON WITH   0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   62,400 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*           11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9   7.4% 12 TYPE OF REPORTING PERSON*   IN *SEE INSTRUCTIONS BEFORE FILLING OUT! Item 1 (a). Name of Issuer: Scinai Immunotherapeutics Ltd. (the “Issuer”) Item 1 (b). Address of Issuer’s Principal Executive Offices: Jerusalem Biopark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem L3 00000 Item 2 (a). Name of Person Filing: Daniel E. Stone Item 2 (b). Address of Principal Business Office or, if None, Residence: 1200 Brickell Avenue, #1470 Miami, FL 33131 Item 2 (c). Citizenship: United States Item 2 (d). Title of Class of Securities: American Depositary Shares, each representing 4,000 Ordinary Shares, no par value Item 2  (e). CUSIP Number: 09073Q203 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance Company as defined in Section 3(a)(19) of the Act; (d) Investment Company registered under Section 8 of the Investment Company Act; (e) Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment plan in accordance with Rule